Table 1.
General Characteristics of Study Participants
| All | Men | Women | |
|---|---|---|---|
| Total no of individuals, n | 12 313 | 5585 | 6728 |
| Complete pairs | 4794 | 2133 | 2661 |
| MZ, n | 3155 | 1353 | 1804 |
| OSDZ, n | 4534 | 2191 | 2343 |
| SSDZ, n | 4588 | 2018 | 2570 |
| UKZ, n | 34 | 23 | 11 |
| Age, y | 64.9 (±8.1) | 65.2 (±8.0) | 64.6 (±8.2) |
| Weight, kg | 74.5 (±13.9) | 81.8 (±12.3) | 68.5 (±12.1) |
| Height, cm | 169.2 (±9.2) | 176.3 (±6.9) | 163.2 (±6.2) |
| Body mass index | 26.0 (±4.1) | 26.3 (±3.7) | 25.7 (±4.4) |
| Current smoker, n | 2021 (16.4%) | 866 (15.5%) | 1155 (17.2%) |
| Previous smoker, n | 4870 (39.6%) | 2504 (44.8%) | 2366 (35.2%) |
| Never smoker, n | 5335 (43.3%) | 2170 (38.9%) | 3165 (47%) |
| Diabetes | 1202 (9.8%) | 687 (12.3%) | 515 (7.7%) |
| Hypertension* | 5901 (47.9%) | 2799 (50.1%) | 3102 (46.1%) |
| Systolic blood pressure, mm Hg | 138.7 (±19.7) | 139.6 (±19.3) | 138 (±20.0) |
| Diastolic blood pressure, mm Hg | 81.9 (±11.0) | 83.1 (±10.6) | 80.9 (±11.3) |
| Pulse pressure, mm Hg | 56.8 (±16.3) | 56.5 (±15.5) | 57.1 (±16.3) |
| Hyperlipidemia* | 9094 (73.9%) | 3654 (65.4%) | 5440 (80.9%) |
| Anti‐hypertensive treatment | 2675 (21.7%) | 1320 (23.6%) | 1355 (20.1%) |
| Statin treatment | 1648 (13.4%) | 911 (16.3%) | 737 (11%) |
| CVD* | 960 (7.8%) | 663 (11.9%) | 297 (4.4%) |
| Waist circumference, cm | 91.3 (±12.2) | 97.0 (±10.2) | 86.6 (±11.6) |
| Waist/hip ratio | 0.89 (±0.13) | 0.94 (±0.13) | 0.84 (±0.11) |
Values are in means±SD or percentage. MZ indicates monozygotic; OSDZ, opposite‐sexed dizygotic; SSDZ, same‐sexed dizygotic; UKZ, unkonown zygosity.
*
Systolic blood pressure >140 mm Hg and/or diastolic blood pressure >90 mm Hg.
*
Total cholesterol >5.0 mmol/L.
*
Cardiovascular disease (defined as ICD10=I20.0, I21, I22, I63; ICD9=410, 411B, 433, 434; ICD8=410, 411, 432, 433, 434; Surgical codes=FNG02, FNG05, FNC, FND, FNE. Diagnosed before study enrollment).